Fagron N.V. : Poor communication, but investment case intact
>Bullish communication during Q1 2021 surprising in hindsight - Fagron’s H1 2021 results were below consensus (8% on REBITDA). Although the REBITDA miss is the result of understandable (and, most importantly, temporary) factors, we were negatively surprised by the H1 results in the context of bullish FY 2021 wording from the company at the presentation of Fagron’s Q1 2021 results. It appears that the company underestimated the timing of the elective care recovery (Jun...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.